Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective-Reference-Cited by-同舟云学术

Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective

Published:2022-04 Issue:4 Volume:30 Page:433-439
ISSN:1319-0164
Container-title:Saudi Pharmaceutical Journal
language:en
Short-container-title:Saudi Pharmaceutical Journal

Author:

Alkhatib Nimer S.^ORCID,Almutairi Abdulaali R.,Alkhezi Omar S.,Alfayez Osama M.^ORCID,Al Yami Majed S.,Almohammed Omar A.

Funder

King Saud University

Publisher

Elsevier BV

Subject

Pharmaceutical Science,Pharmacology

Reference33 articles.

1. Aitken, M., 2016. Improving Type 2 Diabetes Therapy Compliance and Persistence in the Kingdom of Saudi Arabia Find out more [WWW Document]. URL https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/diabetes-reports/improving-type-2-diabetes-therapy-compliance-and-persistence-in-the-kingdom-of-saudi-arabia.pdf.

2. mHealth for diabetes self-management in the Kingdom of Saudi Arabia: barriers and solutions;Alanzi;J. Multidiscip. Healthc.,2018

3. Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis;Alfayez;Cardiovasc. Diabetol.,2020

4. Economic costs of diabetes in Saudi Arabia;Alhowaish;J Family Community Med.,2013

5. Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses;Alzaid;Expert. Rev. Pharmacoecon. Outcomes Res.,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia;Saudi Pharmaceutical Journal;2024-05

2. Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus;World Journal of Diabetes;2024-03-15

3. Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia;Journal of Medical Economics;2024-03-11

4. Burden of Illness of Type 2 Diabetes Mellitus in the Kingdom of Saudi Arabia: A Five-Year Longitudinal Study;Advances in Therapy;2024-01-19

5. Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan;Journal of Medical Economics;2023-06-30